Tag Archives: Alan Carr

Needham Sticks to Its Buy Rating for Cara Therapeutics (CARA)

In a report released today, Alan Carr from Needham maintained a Buy rating on Cara Therapeutics (CARA – Research Report), with a price target of $35.00. The company’s shares closed last Monday at $18.59. According to TipRanks.com, Carr is a

Analysts Offer Insights on Healthcare Companies: Nabriva (NASDAQ: NBRV), Lineage Cell Therapeutics (NYSE MKT: LCTX) and Scholar Rock Holding (NASDAQ: SRRK)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nabriva (NBRV – Research Report), Lineage Cell Therapeutics (LCTX – Research Report) and Scholar Rock Holding (SRRK – Research Report) with bullish

SCYNEXIS (SCYX) Receives a Buy from Needham

Needham analyst Alan Carr maintained a Buy rating on SCYNEXIS (SCYX – Research Report) today and set a price target of $5.00. The company’s shares closed last Monday at $1.16. According to TipRanks.com, Carr is a 1-star analyst with an

Needham Reaffirms Their Buy Rating on Moderna (MRNA)

In a report released today, Alan Carr from Needham maintained a Buy rating on Moderna (MRNA – Research Report), with a price target of $28.00. The company’s shares closed last Monday at $17.38. According to TipRanks.com, Carr is a 1-star

Needham Sticks to Its Buy Rating for Intercept Pharma (ICPT)

Needham analyst Alan Carr maintained a Buy rating on Intercept Pharma (ICPT – Research Report) today and set a price target of $150.00. The company’s shares closed last Monday at $75.23. According to TipRanks.com, Carr is a 1-star analyst with

Needham Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

In a report released today, Alan Carr from Needham maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $135.00. The company’s shares closed last Monday at $86.03. According to TipRanks.com, Carr is a